Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Jorge A. Marrero; Masatoshi Kudo; Alan P. Venook; Sheng-Long Ye; Jean-Pierre Bronowicki; Xiao‐Ping Chen; Lucy Dagher; Junji Furuse; Jean-François H. Geschwind; Laura Ladrón de Guevara; Christos N. Papandreou; Tadatoshi Takayama; Arun J. Sanyal; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Riccardo Lencioni

doi:10.1016/j.jhep.2016.07.020

Related publications

Article2016

Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: <scp>GIDEON</scp> observational study

Masatoshi Kudo, Riccardo Lencioni, Jorge A. Marrero, Alan P. Venook, J.-P. Bronowicki, Xiaoping Chen, Lucy Dagher, Junji Furuse, Jean‐François H. Geschwind, Laura Ladrón de Guevara, Christos N. Papandreou, Arun J. Sanyal, Tadatoshi Takayama, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Sheng‐Long Ye

Article2016

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON

Jean-François H. Geschwind, Masatoshi Kudo, Jorge A. Marrero, Alan P. Venook, Xiao-Ping Chen, Jean-Pierre Bronowicki, Lucy Dagher, Junji Furuse, Laura Ladrón de Guevara, Christos N. Papandreou, Arun J. Sanyal, Tadatoshi Takayama, Sheng-Long Ye, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Riccardo Lencioni

Article2016

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON

Masatoshi Kudo, Masafumi Ikeda, Tadatoshi Takayama, Kazushi Numata, Namiki Izumi, Junji Furuse, Takuji Okusaka, Masumi Kadoya, Satoshi Yamashita, Yuichiro Ito, Norihiro Kokudo

Article2021

P-80 Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON

Markus Peck‐Radosavljevic, Riccardo Lencioni, Kirhan Özgürdal, Masatoshi Kudo

Article2020

Sorafenib Treatment by Child–Pugh Score in Latin American Patients with Hepatocellular Carcinoma

Laura Ladrón de Guevara, Lucy Dagher, Vanessa MV Arruda, Keiko Nakajima, Masatoshi Kudo

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Discussion(0)

Related publications

Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: <scp>GIDEON</scp> observational study

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON

P-80 Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON

Sorafenib Treatment by Child–Pugh Score in Latin American Patients with Hepatocellular Carcinoma